Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matsushita Yuto, Taguchi Satoru, Naiki Taku, Ishikawa Gaku, Nakamura Yu, Miyakawa Jimpei, Nagai Takashi, Kaneko Tomoyuki, Kubota Hiroki, Hoshina Hayato, Kamei Jun, Niimi Aya, Yamada Yuta, Obinata Daisuke, Kakutani Shigenori, Shiozaki Masashi, Ozawa Kento, Noda Michio, Hirata Daichi, Kitagawa Yuichi, Yoshimi Yukihiro, Sugiyama Nozomi, Shimizu Nobuhiko, Tsubouchi Yohei, Sato Keigo, Uchida Kosuke, Watanabe Shinya, Takahashi Jun, Morikawa Toshiharu, Mori Yoichi, Murata Takashi, Murata Taro, Kawai Taketo, Tanaka Takehiro, Uemura Yukari, Takada Tappei, Takahashi Sayuri, Ito Toshiki, Nagata Masao, Miyazaki Hideyo, Kurokawa Satoshi, Yamada Yukio, Sato Ryo, Otsuka Atsushi, Sato Yusuke, Nishimatsu Hiroaki, Umemoto Yukihiro, Furuse Hiroshi, Akiyama Yoshiyuki, Enomoto Yutaka, Takahashi Satoru, Fujimura Tetsuya, Nakagawa Tohru, Fukuhara Hiroshi, Yasui Takahiro, Kume Haruki, Inamoto Teruo
Аннотация
METHODS: We retrospectively analyzed 387 patients with la/m UC who received EV monotherapy and evaluated the prognostic factors using the Cox proportional hazards regression model. We then used the significant factors to derive a system for predicting prognosis.
RESULTS: The median PFS and OS were 7.6 and 14.6 months, respectively. Multivariable analysis revealed six significant factors common to both PFS and OS: poor Eastern Cooperative Oncology Group performance status (≥ 1), presence of aberrant histology (histological subtypes or divergent differentiation), presence of bone metastasis, anemia (hemoglobin < 10 g/dL), high C-reactive protein levels (> 0.5 mg/dL), and hypercalcemia (corrected calcium > 10.2 mg/dL). Based on the number of positive factors, patients were categorized into three groups: 147 patients with none or one factor (low-risk group), 92 patients with two factors (intermediate-risk group), and 148 patients with three or more factors (high-risk group). The log-rank test indicated significant differences in both PFS and OS among the three groups, with C-indices of 0.634 and 0.700 for PFS and OS, respectively.
CONCLUSIONS: Six factors were identified as common prognostic factors for both PFS and OS in la/m UC patients receiving EV monotherapy. The newly developed prognostic risk stratification system based on these factors is clinically useful, particularly for predicting OS.